Lenvatinib adn pembrolizumab for glioblastoma
THere is not sufficient evidence for a combination of lenvatinib and pemroliomab. At the 2020 European Society of Medical Oncology (ESMO) meeting, Lwin et al. presented the results of the LEAP-005 study: a phase II basket trial including 31 patients with rGBM, treated with the association of lenvatinib plus pembrolizumab. The authors reported interesting results: the ORR and the DCR were 16.1% (95% CI, 5.5–33.7) and 58.1% (95% CI, 39.1–75.5), respectively.
THere is not sufficient evidence for a combination of lenvatinib and pemroliomab. At the 2020 European Society of Medical Oncology (ESMO) meeting, Lwin et al. presented the results of the LEAP-005 study: a phase II basket trial including 31 patients with rGBM, treated with the association of lenvatinib plus pembrolizumab. The authors reported interesting results: the ORR and the DCR were 16.1% (95% CI, 5.5–33.7) and 58.1% (95% CI, 39.1–75.5), respectively.
Birzu C, French P, Caccese M, Cerretti G, Idbaih A, Zagonel V, Lombardi G. Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives. Cancers (Basel). 2020 Dec 26;13(1):47.
LBA41 LEAP-005: Phase II Study of Lenvatinib (Len) Plus Pembrolizumab (Pembro) in Patients (PTS) with Previously Treated Advanced Solid Tumours—Annals of Oncology. [(accessed on 7 November 2023)]; Available online: https://www.annalsofoncology.org/article/S0923-7534(20)42353-1/fulltext